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Abstract
Background: Depression has been associated with a higher risk of cardiovascular events and a higher mortality in
patients with one or more comorbidities. This study investigated whether continuative use of antidepressants (ADs),
considered as a proxy of a state of depression, prior to acute myocardial infarction (AMI) is associated with a higher
mortality afterwards. The outcome to assess was mortality by AD use.
Methods: A retrospective cohort study was conducted in the Veneto Region on hospital discharge records with a
primary diagnosis of AMI in 2002–2015. Subsequent deaths were ascertained from mortality records. Drug
purchases were used to identify AD users. A descriptive analysis was conducted on patients’ demographics and
clinical data. Survival after discharge was assessed with a Kaplan-Meier survival analysis and Cox’s multiple
regression model.
Results: Among 3985 hospital discharge records considered, 349 (8.8%) patients were classified as ‘AD users’. The
mean AMI-related hospitalization rate was 164.8/100,000 population/year, and declined significantly from 204.9 in
2002 to 130.0 in 2015, but only for AD users (− 40.4%). The mean overall follow-up was 4.6 ± 4.1 years. Overall, 523
patients (13.1%) died within 30 days of their AMI. The remainder survived a mean 5.3 ± 4.0 years. After adjusting for
potential confounders, use of antidepressants was independently associated with mortality (adj OR = 1.75, 95% CI:
1.40–2.19).
Conclusions: Our findings show that AD users hospitalized for AMI have a worse prognosis in terms of mortality.
The use of routinely-available records can prove an efficient way to monitor trends in the state of health of specific
subpopulations, enabling the early identification of AMI survivors with a history of antidepressant use.
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Background
Coronary heart disease (CHD) is the leading cause of
mortality worldwide, and ranks among the top six causes
of morbidity. Depression accounts for a relevant propor-
tion of the global burden of disease, ranking among the
top three causes, despite a low impact on mortality. In
high-income countries, acute myocardial infarction
(AMI) is the CHD carrying the highest mortality and
morbidity rates [1–4].
In the USA, the age-adjusted hospitalization rates for
CHDs decreased constantly between 2002 and 2013.
Detailed data have shown a drop in the hospitalization
rates for ST-segment elevation myocardial infarction
(STEMI) and a rise in the proportion of hospital admis-
sions for other forms (NSTEMI) in the past decade in
both Europe and the United States [5–7].
A retrospective observational registry study conducted
in Sweden found that the annual incidence rate and
prevalence of depression rose steadily from 1991 to
2010, increasing more rapidly in women than in men
[8]. For both genders, the incidence of clinically-relevant
depressive symptoms increases with age, especially in
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the case of other ongoing comorbidities or
institutionalization [9].
Following an episode of AMI, the incidence of de-
pression ranges widely, from 15 to 30%, for major de-
pressive disorder [10–12], and is around 20% for
dysthymia (minor depression) or depressive symptoms
[13]. Depression has been associated with a higher
risk of cardiovascular events and a higher mortality in
patients with one or more comorbidities [14]. Depres-
sion has been identified as a prognostic risk factor in
CHD: the risk of all-cause mortality and the risk of
cardiovascular events rise by 22 and 13%, respectively
[3, 12]. Another study investigated the impact of de-
pression on mortality after AMI, reporting a mortality
risk at one year of 33% in patients previously diag-
nosed with depression, as opposed to 26% in the
others; and at 19 years after the AMI, the mortality
risk was 87 and 78%, respectively [15].
The occurrence of depression in patients with CHD
substantially increases the likelihood of a worse cardio-
vascular prognosis [16]. Knowing the time frame of de-
pression in relation to patient outcomes would have
important mechanistic and screening implications [17].
Some authors reported that patients with and without a
diagnosis of depression prior to their cardiac event had
similar survival rates [18]. Others found mortality higher
among patients with even mild, clinically insignificant
depressive symptoms prior to their AMI than for those
with no symptoms of depression [19]. A meta-analysis
confirmed that both premorbid and postmorbid depres-
sion are of prognostic significance [17].
In the analysis of the fatality rate after hospitalization
for AMI, another important factor to take into account
is adherence to evidence-based treatment (EBT) for
AMI patients after their discharge from hospital. The
international guidelines recommend a combined and
continuative use of beta-blockers, aspirin/clopidogrel,
statins, and angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers (ACEIs/ARBs) after a
myocardial infarction in order to reduce cardiac morbid-
ity and mortality [20].
The objective of this study was to test the hypothesis
of an association between a continuative use of antide-
pressants, as proxy of a state of depression, prior to the
onset of AMI and a higher mortality afterwards, control-
ling for potential confounders.
Methods
A retrospective cohort study was conducted using ad-
ministrative data routinely collected by the Public
Health District in the Province of Rovigo, in the Ven-
eto Region of Italy. At the time of the study, the Pub-
lic Health District served a population of about
173,000 with an average age of 45.3 years, an old-age
dependency ratio of 193.7%, and a mortality rate of
11.2 per 1000 population.
Sample
Patients were identified in the database on the basis of a
linked anonymized personal code. Inclusion criteria
were: hospitalization between December 1, 2002 and
December 31, 2015, and discharge with a primary diag-
nosis of AMI, based on the International Classification
of Diseases, Ninth Revision [ICD-9-CM] codes 410.xx.
Patients were enrolled in the study only once, on their
first hospitalization (i.e. they had not been admitted to
hospital for AMI during the previous two years). The
follow-up started 30 days after discharge and continued
until time of death or 31/12/2015.
Data sources and definition
Hospital discharge records, coded according to the
ICD-9-CM, were extrapolated for all public and accre-
dited private hospitals in the area. A specific ICD code
(410.7x) was assigned to patients with NSTEMI, while
other codes were used to define patients with STEMI.
Deaths during the follow-up were ascertained from mor-
tality records, coded according to the ICD- 9-CM, from
the Veneto Cause of Death Register. For residents in the
Public Health District of Rovigo the cause of death is
coded, reported, and validated on death certificates by
personnel at the local health agencies. We grouped the
dead in five classes based on the the main cause of
death: (i) malignancy (ICD: 140–239); (ii) endocrine dis-
eases (ICD: 240–279); (iii) cardio-circulatory system ill-
ness (ICD: 390–459); (iv) respiratory illness (ICD: 460–
519); and (v) others (all other ICD) [21].
Drug purchases, based on the Anatomical Therapeutic
Chemical classification (ATC), were used to identify
“users or non-users of antidepressants” and adherence to
therapies.
To classify patients as users or non-users of antide-
pressants, the purchase of antidepressants was used as a
proxy measure of a state of depression. Specifically, ac-
cording to the ATC codes, the following classes of anti-
depressants were considered: non-selective monoamine
reuptake inhibitors (NSMRIs) (ATC code: N06AA), se-
lective serotonin reuptake inhibitors (SSRIs) (ATC code:
N06AB), and other antidepressants (ATC code: N06AX).
Patients were considered as users of antidepressants if
they took this medication continuously for a period
of at least 24 weeks within two years prior to admis-
sion for AMI.
As regards EBT for AMI, beta-blockers (ATC code:
C07), aspirin /clopidogrel (ATC code: B01A), statins (ATC
code: C10) and ACEIs/ARBs (ATC code: C09) were con-
sidered. After discharge, for each class of antidepressants
and for each class of EBT for AMI, drug adherence was
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assessed by means of a medication possession ratio during
the follow-up period, i.e. from the day after hospital dis-
charge to the last day of involvement in the study (end of
study or patient’s death). Specifically, for antidepressants
and beta-blockers, statins and ACEIs/ARBs, we calculated
the proportion of days on which a patient had the medica-
tion available (assuming that one pill a day was necessary),
while aspirin/clopidogrel adherence was measured as the
ratio of the number of dates on which drugs were
prescribed to the number of months in the study. For each
medication class, patients were classified as adherent
(adherence measure > 80%) or nonadherent (otherwise).
Patients were considered as adherent to the combined
EBT for AMI if they had continuously taken medication
from each of the four classes of drugs.
For all patients, comorbidities were identified from all
secondary diagnoses in their hospital discharge records
and graded according to the Charlson Comorbidity
Index (CCI) [22], calculated as the sum of the scores for
the severity of each comorbid condition, and then cate-
gorized as 0, 1, and 2 or more.
Statistical analysis
A descriptive analysis was conducted on patients’
demographics and clinical data. Data were presented
as percentages for categorical variables, and compared
using the chi-square test or Fisher’s exact test, or as
means ± standard deviations (SD), median with inter-
quartile range (IQR) for continuous variables, which
were compared using Student’s t-test for unpaired
data, performing a priori tests for equality of vari-
ances. Baseline clinical characteristics were reported
by age group as follows: up to 65 years old; from 66
to 80 years old; and 80 or older.
Patient survival after hospital discharge was assessed
with a Kaplan-Meier survival analysis. Since it has been
amply demonstrated that 30-day mortality is associated
with AMI-related mortality, patients who died within 30
days of their AMI were excluded from the cumulative
survival analysis. Survival curves were compared using
the log-rank and Breslow tests. To examine the associ-
ation between AD use and the outcomes of interest, we
controlled for potential confounders (age, sex, CCI, type
of AMI, and adherence to EBT for AMI and to anti-
depressant therapy after discharge) using a Cox’s mul-
tiple regression model. To assess the effect of the time
variable on the risk of the event, and to overcome the
hypothesis of intrinsic proportional risks in Cox’s model,
the whole follow-up was divided into shorter time inter-
vals, and a variable representing the period in which the
event occurred was included in the regression model. A
p-value of < 0.05 was accepted as statistically significant.
The analyses were performed using the Statistical Pack-
age for the Social Sciences (SPSS 22.0; SPSS Inc.,
Chicago, USA). Significant trends in the study period of
AMI-related hospitalization were assessed as average an-
nual percent changes (AAPC) [23] using the Joinpoint
Regression Program (JPR Version 4.7.0.0; Statistical
Methodology and Applications Branch, Surveillance
Research Program, National Cancer Institute, USA).
Results
During the study period, 3985 patients at their first
hospitalization and with a primary diagnosis of AMI
were considered. The flow-chart in Fig. 1 summarizes
the patient and study group selection process.
Table 1 shows the study population’s demographic and
baseline clinical characteristics. Overall, of the 3985 pa-
tients included in the analysis, 2428 (60.9%) were male.
The men were significantly younger than the women
(mean 68.2 ± 13.0 years versus 78.0 ± 12.0 years, p < 0.001).
Among the 349 AD users, 48.7% used SSRIs, 20.9% used
NSMRIs, and 30.4% used other ADs. The proportion of
patients classified as “AD users” was significantly higher
for women than for men (13.9% versus 5.4%, respectively,
p < 0.001).
Overall, considering a CCI of 1 ≥ 1, 49.1% of the hos-
pital discharges (1955) involved patients with at least
one comorbidity, with no significant difference between
the groups of patients who were and were not AD users,
but when a CCI ≥2 was considered, this was found sig-
nificantly more often among the AD users (27.5% versus
21.7%, p < 0.05).
During the study period, the mean rate of AMI-related
hospitalizations was 164.8 per 100,000 population a year
(207.7 per 100,000 males, and 124.7 per 100,000 females).
As concerns age, the peak was recorded among adults
aged 80 years and over, with an AMI-related
hospitalization rate of 8.4 per 1000 population a year. In
the period considered, the temporal trend of AMI-related
hospitalizations, and the AAPC in particular, showed a
gradual and significant reduction from 204.9 in 2002 to
130.0 per 100,000 population in 2015, down 36.6% com-
pared to 2002 [AAPC: − 2.7^(− 3.7; − 1.7)].
The temporal trends of the AMI-related
hospitalization rates in patients stratified by AD users
and non-users are shown in Fig. 2. The reduction in
AMI-related hospitalizations was entirely attributable to
the latter group, which saw a 40.4% reduction from 2002
to 2015 [AAPC: − 3.1 (95% CI:− 4.1; − 2.1)], whereas the
trend among the AD users rose by 43.4% [AAPC: 2.3
(95% CI: 0.6; 5.2)].
The overall mean follow-up was 4.6 ± 4.1 years,
while it was 3.2 ± 3.4 years for the AD users group
and 4.7 ± 4.1 years for the other group. Overall, 523
subjects (13.1%) died within 30 days of their AMI,
and for 89.3% of them the cause of death was cardio-
vascular disease.
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For the 3449 patients surviving beyond 30 days after
their discharge from hospital, the mean survival was 5.3
± 4.0 years. As shown in Fig. 3, the mean survival was
shorter among AD users (4.0 ± 3.4 years) than among
non-users (5.4 ± 4.0 years; p < 0.01).
During the follow-up, both all-cause mortality and
cardiovascular-specific mortality were higher among AD
users group than among non-users group (p < 0.01)
(Table 2).
Regarding their EBT for AMI, adherence was sig-
nificantly higher - for each class of medication -
among patients who were not AD users (p < 0.05).
The aspirin/clopidogrel class of EBT for AMI was as-
sociated with the highest adherence in both groups,
irrespective of any use of antidepressants. Considering
the combined EBT for AMI, the overall adherence
was 50.8%, and it was specifically 51.5% among not AD
users, as opposed to 43.1% in the other group (p < 0.05)
(Table 3).
After adjusting for potential confounders, the results
confirmed that use of all three classes of antidepressants
was independently associated with mortality: all ADs (adj
OR = 1.75, 95% CI: 1.40–2.19); NMSRs (adj OR = 1.57,
95% CI: 1.10–2.29); SSRIs (adj OR = 1.71, 95% CI: 1.28–
2.28): and other ADs (adj OR = 1.96, 95% CI: 1.42–2.72).
Mortality was also significantly associated with sex, being
higher among males (adj OR = 1.25, 95% CI: 1.12–1.41);
age (adj OR = 1.06, 95% CI: 1.05–1.07); and CCI (adj
OR = 1.19, 95% CI: 1.16–1.22). Adherence to combined
EBT for AMI had a protective role (adj OR = 0.76, 95% CI:
Fig. 1 Flow-chart of selection process
Table 1 Characteristics of 3985 patients hospitalized for AMI and stratified by AD use
Variables Antidepressant use p value
Yes No
(n. 349) (n. 3636)
Gender [n(%)]
Males 132 (5.4) 2296 (94.6)
Females 217 (13.9) 1340 (86.1) p < 0.05
Age [mean ± (SD)] 76.1 (11.7) 71.6 (13.6) p < 0.05
Follow-up in years [median ± (IQR)] 2.0 (0.2–5.2) 3.8 (0.8–7.7) p < 0.05
Length of stay in days [median ± (IQR)] 10.0 (7.0–16.0) 10.0 (7.0–14.0) p = 0.07
Charlson comorbidity index [n (%)]
0 162 (8.0) 1868 (92.0)
1 91 (8.5) 978 (91.5) p = 0.60
≥ 2 96 (10.8) 790 (89.2) p < 0.05
Acute myocardial infarction [n(%)]
STEMI 199 (8.8) 2066 (91.2)
NSTEMI 150 (8.7) 1570 (91.3) p = 0.94
SD standard deviation, IQR interquartile range, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction
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0.73–0.80), while adherence to antidepressant treatment
after discharge was irrelevant.
Discussion
In our study, the AMI-related hospitalization rate de-
creased constantly during the period investigated, while
among AD users the rate of hospitalization for AMI
remained steady. A similar trend has been observed in
other high-income countries, presumably due to a
marked improvement in the treatment of CHDs in re-
cent decades [24]. The steady rate of AMI-related
hospitalization involving AD users could be explained by
an improvement in the monitoring of antidepressant
medication over the study period too, which may enable
a better definition of depressive status.
The AMI-related hospitalization rate in our study
was higher for men than for women; and males were
younger than females on average. These results are
consistent with the literature, which has drawn atten-
tion to gender-related differences in the occurrence of
AMI [25–27].
About 9% of the patients in our sample had a history of
antidepressant use, and they had a higher mortality after
AMI than patients without this condition. Depressive
Fig. 2 AMI-related hospitalization rate (per 100,000 population) by antidepressant use (2002–2015)
Fig. 3 Survival analysis comparing AD users versus non-users
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disorders are common among people suffering from car-
diovascular diseases and are associated with a broad range
of adverse outcomes. In patients with AMI, depressive
symptoms have emerged as a prognostic risk factor for a
higher cardiovascular-specific mortality, recurrent hospital
admissions, worse general health and well-being, and
higher costs of care, even in the absence of a clinical diag-
nosis of depression [28, 29]. The women in our sample
were more likely to use antidepressants before being
hospitalized for AMI. This finding is consistent with a
multicenter study conducted in Canada, the USA and
Switzerland, in which data were collected on patients
aged 18–55 years using a self-report questionnaire that
included a validated standard tool for assessing depres-
sion [30–33].
Regarding the association between antidepressant use
and the risk of CHD among subjects with no history of
CHD, the results of a meta-analysis provide no evidence
of any association between SSRI or NSMRI use and
CHD risk [34]. Although the use of antidepressants in
patients with CHD helps to control their depression,
their use in this group is controversial. The results of a
meta-analysis nonetheless found that SSRI use in these
patients reduces their depression symptoms and may
improve their CHD prognosis [16].
Patients hospitalized with AMI are at particularly high
risk of mortality, but the mortality rates for patients
hospitalized with heart failure can vary significantly, ran-
ging from 5 to 9% [35]. The prognosis after
hospitalization for AMI is also reportedly very poor, with
a 10-year mortality risk of 48.6% [36]. The 30-day mor-
tality rate of 13.1% seen in our sample could be due to
the patients’ advanced age, and associated chronic condi-
tions. In fact, the sample’s long-term survival was con-
sistent with other published reports.
The association seen between chronic physical condi-
tions and depression is common. Depression has been
associated with a higher incidence of at least one chronic
comorbidity, while people with chronic diseases have
been found more prone to suffer from depression than
people in good health [37, 38]. Our study identified a
better survival rate for patients hospitalized for AMI
with no history of antidepressant treatment. This differ-
ence, was confirmed even after adjusting for age, gender,
CCI, adherence to EBT for AMI, and type of AMI. De-
pression in patients who experience AMI remains a se-
vere condition and warrants treatment and care. Patients
with a history of moderate-severe depressive symptoms
may benefit from adequate treatment, or at least careful
clinical follow-up, after they have been hospitalized for
AMI, in order to monitor any rapid mood swings and
start treatment should symptoms persist.
Patients with depression are less likely to adopt an ad-
equately healthy lifestyle in order to reduce their cardiac
risk after an AMI [39], and nonadherence to medication
is significantly higher among the depressed [40]. Focus-
ing on the evidence-based treatment as a whole, the pro-
portions of patients adhering to the combined EBT for
AMI were much the same as in other studies, and our
findings confirm the positive effects of EBT for AMI on
survival after AMI [20].
Our results show that it is important to identify AMI
patients at high risk of depression, so that they can be
targeted for depression screening, and benefit from ap-
propriate treatment in relation to their baseline condi-
tions [18]. In our study, there was no difference in
mortality between patients who were or were not given
continuative antidepressants after discharge. This finding
Table 2 Distribution of 1322 patients who died, by antidepressant use and cause of death
Cause of death Antidepressant use Total (n. 3449)
Yes (n. 281) No (n. 3168)
n (%) n (%) n (%)
Cardiocirculatory system illness 96 (34.2) 760 (24.0) 856 (24.8)
Malignancy 9 (3.2) 175 (5.5) 184 (5.3)
Endocrine diseases 3 (1.1) 63 (2.0) 66 (1.9)
Respiratory illness 4 (1.4) 49 (1.5) 53 (1.5)
Others 29 (10.3) 134 (4.2) 163 (4.7)
All deaths 141 (50.2) 1181 (37.3) 1322 (38.3)
Denominator of percentuage is the number of patients surviving beyond 30 days after their discharge from hospital (in the column)
Table 3 Adherence to AMI evidence-based treatment in the
follow-up of 3449 patients
EBT class Antidepressant use Total (n. 3449)
Yes (n. 281) No (n. 3168)
n (%) n (%) n (%)
Aspirin/Clopidogrel 242 (86.1) 2879 (90.9) 3121 (90.5)
Beta-blockers 185 (65.8) 2308 (72.9) 2493 (72.3)
Statins 176 (62.6) 2293 (72.4) 2469 (71.6)
ACEIs/ARBs 184 (65.5) 2344 (74.0) 2528 (73.3)
Combination EBT 121 (43.1) 1630 (51.5) 1751 (50.8)
EBT evidence-based treatment, ACEIs angiotensin-converting enzyme
inhibitors, ARBs angiotensin receptor blockers
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is consistent with another study that examined the tim-
ing of antidepressant prescription vis-à-vis the time of
hospital discharge after AMI [19]. It is still by no means
clear whether managing any depression can improve
survival after AMI, and clinical trials on this issue are
obviously needed, also to ascertain the most appropriate
treatment for post-AMI depression. Currently-available
evidence nonetheless indicates that psychotherapy and
psychoactive pharmacological treatments are both safe
and effective in reducing depression in patients with car-
diovascular diseases [41].
A limitation of our study lies in that patients were
identified as AD users (considered as a proxy for a state
of depression) on the basis of their having purchased an-
tidepressants for more than 24 consecutive weeks prior
to their hospitalization for AMI, not on the grounds of a
clinical diagnosis. The threshold of 24 weeks has been
adopted by several clinical practice guidelines as an indi-
cation of treatment for chronically depressed patients,
however [42]. A clinical assessment of the severity of
AMI was also lacking in our study. The main strength of
our study, on the other hand, concerns the AMI popula-
tion analyzed, which was numerically large, well defined,
and followed up for several years after discharge from
hospital.
Conclusions
Our findings show that AD users hospitalized for AMI
have a worse prognosis in terms of mortality. The use of
routinely-available records can prove an efficient way to
monitor trends in the state of health of specific subpop-
ulations, enabling the early identification of AMI survi-
vors with a history of depression.
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